NICE Technology Appraisals in the NHS in England - to September 2014, Experimental statistics, Innovation scorecard

The Innovation Scorecard aims to improve transparency within the NHS of what treatments recommended by NICE are available within Trusts and CCGs and at National and Area Team level. It is intended to support monitoring of compliance with NICE Technology Appraisal (TA) recommendations and to assist the NHS in the identification of variation, which can be explained, challenged or acted upon. It is not intended to be used for performance management.

The Innovation Health and Wealth Strategy set out plans to support development and adoption of innovation in the NHS. The National Institute for Health and Care Excellence (NICE) technology appraisal process assesses the clinical and cost effectiveness of new and existing medicines and treatments, and provides guidance on their use by the NHS.

There is no central collection of data which can directly support the assessment of uptake of NICE recommendations, nor is data on the number of patients treated available. Therefore this is an experimental publication, which makes use of data currently available from a range of sources, both from the NHS and the commercial sector. The HSCIC welcomes comments and suggestions from users to support future development of appropriate datasets and reporting.

The data is presented in the form of two interactive spreadsheets which use macros to allow users to identify the organisations, interventions and time periods they wish to explore. The data is also presented in tables, charts and maps to identify trends and variation. A 'How to...' tab on the interactive spreadsheets explains how to use them.

An accompanying report describes the data, the sources and its limitations. Please note that the interactive spreadsheets should be viewed in conjunction with the report, and the caveats to interpretation should be noted.

In addition, an estimates report looks at the use of a range of appraised medicines in relation to the number of eligible patients as estimated by NICE.

Please note that an estimate for Alitretinoin was planned for inclusion in this report. However, due to concerns over some of the evidence used as the basis of the estimate, it has been withheld from publication. NICE and the HSCIC are working to update this estimate and will provide updates in future publications.

Additional information is available in an FAQ format.

The first Innovation Scorecard was published in January 2013, using data from 2011. The second publication in September 2013 reported data for 2012. The Innovation Scorecard has since been published on a quarterly basis, showing data for additional quarters since October 2013. It has also developed over this time to include new treatments recommended by NICE and by enhancements to the format and presentation.

Please note that data for 10 medicines (Bendamustine, Bortezomib, Cetuximab, Infliximab, Ipilimumab, Oxaliplatin, Pemetrexed, Rituximab, Topotecan and Trastuzumab) have not been included in this publication due to concerns around the quality of some of the underlying data received by the HSCIC. The HSCIC are in discussion with the data supplier to resolve these issues and data for these medicines will be included in future publications.

Note that due to the size of the spreadsheets, they may take a few moments to open.

NHS England has released additional maps. See the link provided below.